Translating Metastasis Research into Incredible New Therapies
1% of cancer research papers focus on metastatic cancer • Less than 5% of cancer funding goes towards tackling metastatic cancer • The clinical success rate of cancer drugs has dropped to 3.4% • 90% of cancer patients who die, do so from cancer metastasis
There’s no doubt about it. This is a huge area of need.
Tackling metastatic cancer represents the greatest opportunity to improve the lives of most cancer patients. And for the first time we now have the opportunity to pull together as an oncology community and make real progress for patients.
“The most exciting oncology meeting to happen in years”
Immuno-oncology/CAR-T • New metastatic models • A groundswell of translational anti-metastatic research • AI • The quest for new oncology targets • New insights in cancer cell metabolism • A declining clinical success rate • Fresh thinking around clinical trials • New early-diagnostic technologies • The emerging influence of the microbiome.
These are all drivers that are converging to open up incredible new therapeutic opportunities in tackling metastasis. And this meeting address each of these topics and more with a an unrivalled speaker line-up and in a friendly, welcoming environment conducive to deep learning and networking.
This is an event for the entire oncology community – pharma, researchers and clinicians – to move beyond basic research and focus on the development of new therapies that tackle cancer where it hits hardest.
J. Carl Barrett
Global Lead Translational Medicine Oncology R&D
Professor of Cancer Biology
Daniel K. Ludwig Professor for Cancer Research
Senior Scientist, Biological Sciences, Odette Cancer Research Program
Sunnybrook Research Institute
Maria A.S Broggi
Exploratory Immuno-Oncology Investigator
Novartis Institutes for BioMedical Research
Founder and Head of Research
Scientist, CAR T Discovery and Platform Development
The Janssen Pharmaceutical Companies of Johnson & Johnson
Chief Scientific Officer
Distinguished Scientist and Head, Translational Medicine
Andrew P Mazar
Chief Scientific Officer
Associate Director, Center for Patient Derived Models
Dana-Farber Cancer Institute
Unlock New Therapeutic Avenues
Explore new targets, mechanisms and modalities.
Shape Your Strategy Using Experts
Learn from the world’s leading cancer researchers.
Improve Clinical Success
Optimize metastatic model use, discover new endpoints and trial paradigms.
Make New Connections
Network with experts from academia, healthcare and pharma.
Key Topics Include
Translate metastasis research into the clinic. Understand which targets, mechanisms and therapeutic avenues hold the most promise.
Implement metastatic models. Uncover clinically-relevant findings from new and emerging models of metastatic disease, and improve modelling to tackle immune-oncology toxicity.
Stop metastasis earlier. Learn how and why, coupled with new methods to detect cancer, the potential to stop metastasis before it’s too later is increasing.
AI and metastasis. What if AI could help rethink the metastasis/resistance equation? Find out how.
Biomarkers and metastasis. Explore new methods to select drug candidates, new biomarkers for metastasis and which biomarkers are most likely to be meaningful for patients.
Dormancy. Discover the most therapeutically relevant advances in our understanding of dormancy in metastasis.
Immuno-oncology and metastasis. As metastasis research and CAR-T therapies converge, understand how new CAR-T cells are being generated for the eradication of advanced cancers.
Cancer as a metabolic disease. Learn about the prospects for metabolic therapies, including the most likely targets and pathways.
Overcoming anti-metastatic bottlenecks. Discuss how to overcome the barriers and bottlenecks to drive the development of therapies that tackle metastasis.
The microbiome and metastasis. Uncover the impact of microorganisms in carcinogenesis, cancer progression and metastasis, and the therapeutic implications of recent findings.
Endpoints and clinical trials. Define the relationship between established and novel tumor-based endpoints with overall survival rates in patients treated with immunotherapy, and discover/discuss new trial paradigms and endpoints.
Leverage data-driven approaches. Streamline big data research into clinically actionable interventions for the treatment of metastatic disease.